TRUE Private Wealth Advisors Invests $208,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

TRUE Private Wealth Advisors purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,572 shares of the biopharmaceutical company’s stock, valued at approximately $208,000.

A number of other hedge funds have also recently made changes to their positions in the stock. PCA Investment Advisory Services Inc. bought a new position in Gilead Sciences in the 2nd quarter valued at approximately $25,000. OFI Invest Asset Management bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $26,000. Tompkins Financial Corp lifted its position in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares in the last quarter. Fortitude Family Office LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Finally, Sanctuary Wealth Management L.L.C. purchased a new stake in Gilead Sciences during the 4th quarter valued at $33,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 1.2 %

GILD opened at $66.16 on Friday. The firm has a 50-day simple moving average of $72.10 and a two-hundred day simple moving average of $76.58. Gilead Sciences, Inc. has a 52 week low of $65.90 and a 52 week high of $87.86. The company has a market capitalization of $82.37 billion, a PE ratio of 14.70, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the previous year, the business posted $1.67 EPS. The firm’s revenue was down 3.7% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post 6.55 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.66%. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GILD. Barclays reduced their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, February 12th. Oppenheimer reduced their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, February 12th. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. Royal Bank of Canada reduced their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. Finally, StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $84.71.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.